造血干细胞移植用于治疗淋巴系统恶性血液病  

Effect of Hematopoietic Stem Cell Transplantation in Malignant Hematologic Disease of Lymphatic System

作　　者：宋慧慧[1] 陈宝安[1] 丁家华[1] 孙雪梅[2] 高冲[1] 孙耘玉[1] 王骏[1] 程坚[1] 赵刚[1] 

机构地区：[1]东南大学附属中大医院血液科,南京210009 [2]鼓楼医院血液科,南京210008

出　　处：《中国实验血液学杂志》2006年第5期945-948,共4页Journal of Experimental Hematology

基　　金：江苏省自然科学基金资助项目(编号BK1999126);江苏省卫生厅科技发展基金资助项目(编号H200344);南京市重大课题资助项目(编号YQ0008);东南大学中大医院重大课题资助项目(编号2003-Yj02)

摘　　要：本研究探讨造血干细胞移植(HSCT)对恶性淋巴系统血液病的疗效。通过8例非霍奇金淋巴瘤(NHL)及3例淋巴细胞白血病患者在前期化疗基础上进行造血干细胞移植,分别观察造血重建、并发症及生存期等指标,以了解造血干细胞移植对该类疾病的疗效。结果表明:HSCT后11例患者(其中自体移植7例,异基因移植4例)造血顺利恢复,均能达到完全缓解(CR)。随访3年,5例NHL患者无病生存,1例NHL患者于移植后2个月死亡,1例自杀;4例接受异基因造血干细胞移植的患者中,1例非霍奇金淋巴瘤(NK细胞型)移植后79天死亡,1例慢性淋巴细胞白血病患者无病生存,2例急性淋巴细胞白血病患者分别于移植后第54天、第17个月死亡。结论:造血干细胞移植是治疗恶性淋巴系统血液疾病的一个有效手段,但自体HSCT的患者尚有一定的复发率,而异基因HSCT患者有可能因严重的移植相关并发症而死亡。The study was aimed to investigate the effect of hematopoietic stem cells transplantation （HSCT） in treatment for hematologic maglignacies of lymphatic system. Through observing 8 patients with non-Hodgkin＇s lymphoma （NHL） and 3 patients with lymphoblastic leukemia, who received auto or allo-HSCT after chemotheraphy, the hematopoietic reconstitution, complication and surviral time were evaluated. The results showed that 11 patients （7 patients after auto-PBSCT, 4 patients after aIIo-PBSCT） all achieved hematopoietic reconstitution and complete remission （CR）. Within three years following-up, 5 patients with NHL were survival, but one case of NHL died at the 2 months after auto-PBSCT, one patient suicided. From 4 cases received aIlo-PBSCT, one patiant with NHL （ NK cell） was died at 79 days later, one patient with chronic lymphoblastic leukemia was surviving, another 2 cases of acute lymphoblastic leukemia were dead at 17 months and 54 days respectively after aIIo-PBSCT. In conclusion HSCT is an effective treatment for hematologic maglignancies of lymphatic system, but the replase would occur in some patients received auto- PBSCT. The others by allo-PBSCT might die of severe complication of transplantation.

关 键 词：造血干细胞移植 淋巴瘤 淋巴细胞白血病 

分 类 号：R457.7[医药卫生—治疗学] R733[医药卫生—临床医学]